Evidence map›Paper›PMID 41436446›Full record

ArticleNature communications2025

Prostate cancer cells converge to an inflammatory-like state upon metastatic dissemination.

Tina Keshavarzian, Kira Furlano, Giacomo Grillo, Lisanne Mout, Christopher Arlidge, Faizan Hasan, Ankita Nand, Migle Mikutenaite, Evdoxia Karadoulama, Ashish Goyal and 12 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Tina Keshavarzian *Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Kira Furlano *Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-1724-7061
Giacomo GrilloPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Lisanne MoutPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Christopher ArlidgePrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Faizan HasanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Ankita NandPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-7071-5114
Migle MikutenaiteBiotech Research & Innovation Centre (BRIC), The Finsen Laboratory, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Evdoxia KaradoulamaBiotech Research & Innovation Centre (BRIC), The Finsen Laboratory, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Ashish GoyalDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-9830-3987
Elisabeth L PezzutoDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jessica HeilmannDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jakub SykoraDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sarah MinnerDepartment of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thorsten SchlommDepartment of Urology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0001-9557-4653
Guido SauterDepartment of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ronald SimonDepartment of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Housheng Hansen HePrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-2898-3363
Joachim WeischenfeldtDepartment of Urology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-3917-5524
Christoph PlassDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0003-2554-3952
Clarissa GerhäuserDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany. c.gerhauser@dkfz-heidelberg.de.ORCID http://orcid.org/0000-0002-5792-3901
Mathieu LupienPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. mathieu.lupien@uhn.ca.ORCID http://orcid.org/0000-0003-0929-9478

Funding

Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) 153234, 158225, 168933, 191847Ontario Institute for Cancer Research (Institut Ontarien de Recherche sur le Cancer) IA-031
6 · The paper itself

Abstract

Identifying drivers of cancer progression to guide treatment selection is hindered by our limited understanding of tumor heterogeneity and its impact on tumor evolution. Here, we delineate the phenotypic variability across ~300,000 cells collected from multiple tumor loci in primary prostate and matched locoregional metastases using single-cell chromatin accessibility and gene expression sequencing. We find inter-patient heterogeneity to be confined to malignant populations. Within individual tumor loci, we see phenotypic heterogeneity among malignant cell populations despite a shared clonal genotypic architecture. We also observe that malignant cell populations disseminating to locoregional lymph nodes mirror the clonal architecture and phenotypic heterogeneity across primary tumor loci, while shifting from canonical prostate-cancer states to non-canonical inflammatory-like states. Our findings suggest a bottleneck imposed during the dissemination process, funneling prostate cancer cells toward an inflammatory-like cell state. These insights into the interplay between phenotypic identity and clonal architecture refine our understanding of prostate cancer progression and suggest that convergence of cancer cells towards an inflammatory-like state underlies dissemination to lymph nodes, offering a critical framework for future studies into prostate cancer metastatic potential.

Indexed as

InflammationProstatic NeoplasmsDisease ProgressionGene Expression Regulation, NeoplasticHumansLymphatic MetastasisLymph NodesMaleNeoplasm MetastasisPhenotypeSingle-Cell Analysis

Identifiers

PMID41436446
PMCPMC12728229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.